Regenxbio
RGNX
186 hedge funds and large institutions have $1.51B invested in Regenxbio in 2019 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 69 increasing their positions, 61 reducing their positions, and 43 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 61
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.46% less ownership
Funds ownership: 82.86% → 80.4% (-2.5%)
11% less call options, than puts
Call options by funds: $11.3M | Put options by funds: $12.7M
12% less funds holding
Funds holding: 211 → 186 (-25)
13% less capital invested
Capital invested by funds: $1.73B → $1.51B (-$219M)
51% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 43
Top Buyers
| 1 |
CG
Carmignac Gestion
Paris,
France
|
+$37.1M |
| 2 |
Korea Investment Corp
Seoul,
South Korea
|
+$20.1M |
| 3 |
State Street
Boston,
Massachusetts
|
+$19M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$10.7M |
| 5 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$10.3M |
Top Sellers
| 1 |
Renaissance Technologies
New York
|
-$25.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$19.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.8M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$13.5M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$12.7M |
RGNX Hedge Fund Activity: Q2 2019 in Review
186 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q2 2019, worth a combined $1.51B — down 13% from $1.73B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of RGNX and 21 opened new positions — a net loss of 22 holders — while 61 trimmed existing stakes and 69 added.
The largest buyer was Carmignac Gestion, adding an estimated $37.1M. The largest seller was Renaissance Technologies, cutting an estimated $25.9M.
- 186 institutional investors held Regenxbio (RGNX) as of Q2 2019, down from 211 in Q1 2019.
- Funds reported $1.51B of Regenxbio stock for Q2 2019, down 13% quarter-over-quarter.
- 21 funds opened new Regenxbio positions in Q2 2019 and 43 closed out, a net change of -22 holders.
- The largest Regenxbio buyer in Q2 2019 was Carmignac Gestion, an estimated $37.1M added.
- The largest Regenxbio seller in Q2 2019 was Renaissance Technologies, an estimated $25.9M sold.
Based on aggregated 13F filings for Q2 2019.